News
aTyr's lead drug, efzofitimod, just completed enrollment in its phase 3 EFZO-FIT trial for pulmonary sarcoidosis, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback